Patient Safety and Quality Assurance
What this domain tests
Quality assurance items ask whether the pharmacy has a real system for catching, analyzing, and learning from medication errors, and whether the pharmacist knows which external reporting channel applies. New Hampshire expects more than a binder: a written continuous quality improvement program, documented review, and reporting of quality-related events to the Board.
Building blocks
- Internal reporting: any staff member can report an error or a near miss without fear of retaliation; reports are reviewed promptly by the pharmacist-in-charge or a quality committee.
- Root cause analysis: ask why the system permitted the error - look-alike labels, similar names, staffing at transition times, unclear directions - rather than stopping at "the technician misread it."
- Corrective actions: change the process (separation of look-alikes, barcode scanning, double counts for high-risk drugs), then verify the change worked.
- Documentation: keep the record of the event, the analysis, and the follow-up; distinguish the internal quality record from the Board report.
External reporting channels
- New Hampshire Board of Pharmacy: quality-related events under the Board's CQI rules.
- FDA MedWatch: serious adverse drug events and product problems.
- VAERS: adverse events after vaccination.
- Manufacturer and DEA: for product tampering or controlled substance loss, respectively.
Worked example
A pharmacist catches a tenfold dosing error before the bag leaves the counter. Reasoning: this is a near miss, not a non-event. It goes into the internal quality system, triggers a review of how the similar-strength products are stored, and generates a documented corrective action. A near miss that reveals a system flaw is exactly the kind of event a good program captures, and the pharmacist should not wait for a harm event to act.
Traps that cost marks
Treating a near miss as unreportable. Disciplining the individual and closing the file without a system fix. Sending an adverse event only to the manufacturer when MedWatch is the required channel. Confusing the internal quality record with the Board report, or assuming that internal review substitutes for external reporting.